Tick-borne encephalitis (TBE) is a vector-borne infection associated with a variety of potentially serious complications and sequelae. Vaccination against TBE is strongly recommended for people living in endemic areas. There are two TBE vaccination schemes - standard and rapid - which differ in the onset of protection. With vaccination in a rapid schedule, protection starts as early as 4 weeks after the first dose and is therefore especially recommended for non-immune individuals travelling to endemic areas. Both schemes work reliably in immunocompetent individuals, but only little is known about how TBE vaccination works in people with HIV infection. Our aim was to assess the immunogenicity and safety of the rapid scheme of TBE vaccination in HIV-1 infected individuals. Concentrations of TBE-specific IgG > 126 VIEU/ml were considered protective. The seroprotection rate was 35.7% on day 28 and 39.3% on day 60. There were no differences between responders and non-responders in baseline and nadir CD4 + T lymphocytes. No serious adverse events were observed after vaccination. The immunogenicity of the TBE vaccination was unsatisfactory in our study and early protection was only achieved in a small proportion of vaccinees. Therefore, TBE vaccination with the rapid scheme cannot be recommended for HIV-1 infected individuals.

Department of Biostatistics National Institute of Public Health Šrobárova 48 100 42 Prague10 Czech Republic

Department of Infectious and Tropical Diseases 1st Faculty of Medicine Charles University Prague and Nemocnice Faculty Hospital Bulovka Budinova 48 2 180 81 Prague 8 Czech Republic

Department of Infectious Diseases 3rd Faculty of Medicine Charles University Prague and Nemocnice Faculty Hospital Bulovka Budinova 48 2 180 81 Prague 8 Czech Republic

Department of Infectious Diseases University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Beaute J et al. (2018) Tick-borne encephalitis in Europe, 2012 to 2016. Eurosurveillance 23, 1800201. PubMed PMC

Taba P et al. (2017) EAN Consensus review on prevention, diagnosis and management of tick-borne encephalitis. European Journal of Neurology 24, 1214–e1261. PubMed

Bogovic P et al. (2018) Factors associated with severity of tick-borne encephalitis: a prospective observational study. Travel Medicine and Infectious Disease 26, 25–31. PubMed

Heinz FX et al. (2007) Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25, 7559–7567. PubMed

Steffen R (2016) Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations. Journal of Travel Medicine 23, 1–10. PubMed

Loew-Baselli A et al. (2011) Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 29, 7307–7319. PubMed

Velay A et al. (2018) A new hot spot for tick-borne encephalitis (TBE): a marked increase of TBE cases in France in 2016. Ticks and Tick-borne Diseases 9, 120–125. PubMed

Demicheli V, Debalini MG and Rivetti A (2009) Vaccines for preventing tick-borne encephalitis. Cochrane Database Systematic Reviews 1, CD000977. PubMed PMC

Schosser R et al. (2014) Irregular tick-borne encephalitis vaccination schedules: the effect of a single catch-up vaccination with FSME-IMMUN. A prospective non-interventional study. Vaccine 32, 2375–2381. PubMed

Jelinek T (2012) TBE – update on vaccination recommendations for children, adolescents, and adults. Wiener Medizinische Wochenschrift 162, 248–251. PubMed

Zent O et al. (2003) Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 21, 4655–4660. PubMed

Zent O and Broker M (2005) Tick-borne encephalitis vaccines: past and present. Expert Review of Vaccines 4, 747–755. PubMed

Schondorf I et al. (2007) Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25, 1470–1475. PubMed

Beran J et al. (2004) Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule. International Journal of Medical Microbiology 293(suppl. 37), 130–133. PubMed

Harabacz I et al. (1992) A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens. Vaccine 10, 145–150. PubMed

Buhler T et al. (2019) Febrile illness and bicytopenia within hours after tick-borne encephalitis booster vaccination. NPJ Vaccines 4, 52. PubMed PMC

Geretti AM et al. (2018) British HIV association guidelines on the use of vaccines in HIV-positive adults 2015. HIV Medicine 17(suppl. 3), s2–s81. PubMed

Crum-Cianflone NF and Sullivan E (2017) Vaccinations for the HIV-infected adult: a review of the current recommendations, part I. Infectious Diseases and Therapy 6, 303–331. PubMed PMC

Panasiuk B, Prokopowicz D and Panasiuk A (2003) Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 31, 45–46. PubMed

Wolf HM et al. (1992) Cellular and humoral immune responses in haemophiliacs after vaccination against tick-borne encephalitis. British Journal of Haematology 82, 374–383. PubMed

Stiasny K et al. (2012) Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS ONE 7, e34145. PubMed PMC

Baldovin T et al. (2012) Persistence of immunity to tick-borne encephalitis after vaccination and natural infection. Journal of Medical Virology 84, 1274–1278. PubMed

Paulke-Korinek M et al. (2013) Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. Vaccine 31, 1293–1297. PubMed

Garner-Spitzer E et al. (2013) Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10. Journal of Immunology 191, 2426–2436. PubMed

Holzmann H et al. (1996) Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. Journal of Medical Virology 48, 102–107. PubMed

Litzba N et al. (2014) Evaluation of different serological diagnostic methods for tick-borne encephalitis virus: enzyme-linked immunosorbent, immunofluorescence, and neutralization assay. Vector-Borne and Zoonotic Diseases 14, 149–159. PubMed

Zent O et al. (2003) Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine 21, 3584–3592. PubMed

Galgani I et al. (2017) Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules. Expert Review of Vaccines 16, 919–932. PubMed

Jilkova E et al. (2009) Serological response to tick-borne encephalitis (TBE) vaccination in the elderly – results from an observational study. Expert Opinion on Biological Therapy 9, 797–803. PubMed

Dengler TJ et al. (1999) Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 17, 867–874. PubMed

Zielinski CC et al. (1986) Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer 58, 1648–1652. PubMed

Hertzell KB et al. (2016) Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Vaccine 34, 650–655. PubMed

Rendi-Wagner P et al. (2007) Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 25, 5097–5101. PubMed

Zent O et al. (2004) TBE Booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary? Vaccine 23, 312–315. PubMed

Lange CG et al. (2003) Nadir CD4 + T-cell count and numbers of CD28 + CD4 + T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS (London, England) 17, 2015–2023. PubMed

Deeks SG (2011) HIV Infection, inflammation, immunosenescence, and aging. Annual Review of Medicine 62, 141–155. PubMed PMC

Aberle JH et al. (2013) Mechanistic insights into the impairment of memory B cells and antibody production in the elderly. Age (Dordr) 35, 371–381. PubMed PMC

Litjens NH et al. (2008) IL-2 producing memory CD4 + T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. Journal of Immunology 181, 3665–3673. PubMed

Hansson KE et al. (2020) Tick-borne encephalitis vaccine failures: a 10-year retrospective study supporting the rationale for adding an extra priming dose in individuals starting at age 50 years. Clinical Infectious Diseases 70, 245–251. PubMed PMC

Hopf S et al. (2016) Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine. Vaccine 34, 2027–2034. PubMed